Here's Why Johnson & Johnson Is Still in the Coronavirus Vaccine Race

Here's Why Johnson & Johnson Is Still in the Coronavirus Vaccine Race
Alex Carchidi, The Motley Fool

Even with a late start, their vaccine might beat Moderna and Pfizer in terms of price and convenience.